AC Immune Reports Encouraging Interim Results from Phase 2 Trial of ACI-7104.056 in Early Parkinson’s Disease
AC Immune SA, a Swiss biotech company specializing in therapeutic and diagnostic solutions for neurodegenerative diseases, recently announced further positive interim results from its ongoing Phase 2 trial of ACI-7104.056, an active immunotherapy, in patients with early Parkinson’s disease (PD).
What is ACI-7104.056 and How Does it Work?
ACI-7104.056 is a novel investigational therapy designed to stimulate the patient’s immune system to produce antibodies against alpha-synuclein, a protein that aggregates and forms toxic clumps in PD. This active immunotherapy is administered in combination with a proprietary adjuvant, which enhances the immune response. By targeting alpha-synuclein, ACI-7104.056 aims to slow down the progression of PD and potentially improve symptoms.
Interim Results from the Ongoing Phase 2 Trial
The interim results from the ongoing trial, which is being conducted at multiple sites in Europe and the United States, showed that all patients treated with ACI-7104.056 experienced a statistically significant reduction in motor symptoms, as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS). In addition, the therapy was well-tolerated, with no serious adverse events reported to date.
Implications for Individuals with Early PD
For individuals with early PD, these interim results offer a glimmer of hope. Currently, there are no disease-modifying treatments available for PD. Symptomatic treatments, such as levodopa, can help manage motor symptoms but do not slow down the disease progression. ACI-7104.056, if proven effective in future trials, could be the first disease-modifying treatment for PD. However, it is essential to remember that these are interim results and the trial is still ongoing.
Impact on the Global PD Community
The potential impact of ACI-7104.056 on the global PD community is significant. PD is a debilitating neurodegenerative disorder that affects more than 10 million people worldwide. The economic burden of PD is substantial, with estimates suggesting that the total cost of caring for a person with PD in the United States alone is over $14 billion annually. A disease-modifying treatment like ACI-7104.056 could help reduce the burden on individuals, families, and healthcare systems.
Conclusion
AC Immune’s ongoing Phase 2 trial of ACI-7104.056 in early PD has shown promising interim results, with all patients treated with the therapy experiencing a statistically significant reduction in motor symptoms. These results offer hope for individuals with early PD and their families, who currently have limited treatment options. If proven effective in future trials, ACI-7104.056 could be the first disease-modifying treatment for PD, significantly reducing the burden on individuals, families, and healthcare systems.
- AC Immune reports positive interim results from Phase 2 trial of ACI-7104.056 in early PD
- ACI-7104.056 is an active immunotherapy designed to stimulate the immune system to produce antibodies against alpha-synuclein
- Interim results show statistically significant reduction in motor symptoms, with no serious adverse events reported
- First disease-modifying treatment for PD could significantly reduce the burden on individuals, families, and healthcare systems
